Switch theme
Sign up to access all valuation multiples
Japan Lifeline Co Ltd is a medical device company operating in Japan. It is engaged in the trading and manufacturing of medical devices specialized in the cardiovascular field. The company offers medical devices mainly for the treatment of cardiac and vascular diseases. It focuses on providing implantable devices to treat arrhythmias; disposable catheter devices with electrodes for diagnosis and treatment of arrhythmias; prosthetic devices to replace blood vessels and heart valves that lost their functions; and devices for intravascular treatment of cardiac infarction, arterial occlusions of the lower extremities and congenital cardiac diseases.
1981
1.2K+
LTM Revenue $392M
LTM EBITDA $98.9M
$650M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Japan Lifeline has a last 12-month revenue (LTM) of $392M and a last 12-month EBITDA of $98.9M.
In the most recent fiscal year, Japan Lifeline achieved revenue of $353M and an EBITDA of $82.8M.
Japan Lifeline expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Japan Lifeline valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $392M | XXX | $353M | XXX | XXX | XXX |
| Gross Profit | $237M | XXX | $213M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $98.9M | XXX | $82.8M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $85.9M | XXX | $74.8M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $64.4M | XXX | $51.6M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Japan Lifeline's stock price is JPY 1453 (or $10).
Japan Lifeline has current market cap of JPY 102B (or $699M), and EV of JPY 94.7B (or $650M).
See Japan Lifeline trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $650M | $699M | XXX | XXX | XXX | XXX | $0.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Japan Lifeline has market cap of $699M and EV of $650M.
Japan Lifeline's trades at 1.8x EV/Revenue multiple, and 8.0x EV/EBITDA.
Equity research analysts estimate Japan Lifeline's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Japan Lifeline has a P/E ratio of 10.9x.
See valuation multiples for Japan Lifeline and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $699M | XXX | $699M | XXX | XXX | XXX |
| EV (current) | $650M | XXX | $650M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 6.6x | XXX | 8.0x | XXX | XXX | XXX |
| EV/EBIT | 7.6x | XXX | 8.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.9x | XXX | 13.8x | XXX | XXX | XXX |
| EV/FCF | 12.8x | XXX | 16.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJapan Lifeline's last 12 month revenue growth is 6%
Japan Lifeline's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Japan Lifeline's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Japan Lifeline's rule of X is 39% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Japan Lifeline and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Japan Lifeline acquired XXX companies to date.
Last acquisition by Japan Lifeline was XXXXXXXX, XXXXX XXXXX XXXXXX . Japan Lifeline acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Japan Lifeline founded? | Japan Lifeline was founded in 1981. |
| Where is Japan Lifeline headquartered? | Japan Lifeline is headquartered in Japan. |
| How many employees does Japan Lifeline have? | As of today, Japan Lifeline has 1.2K+ employees. |
| Who is the CEO of Japan Lifeline? | Japan Lifeline's CEO is Mr. Keisuke Suzuki. |
| Is Japan Lifeline publicy listed? | Yes, Japan Lifeline is a public company listed on TKS. |
| What is the stock symbol of Japan Lifeline? | Japan Lifeline trades under 7575 ticker. |
| When did Japan Lifeline go public? | Japan Lifeline went public in 1997. |
| Who are competitors of Japan Lifeline? | Similar companies to Japan Lifeline include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Japan Lifeline? | Japan Lifeline's current market cap is $699M |
| What is the current revenue of Japan Lifeline? | Japan Lifeline's last 12 months revenue is $392M. |
| What is the current revenue growth of Japan Lifeline? | Japan Lifeline revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Japan Lifeline? | Current revenue multiple of Japan Lifeline is 1.7x. |
| Is Japan Lifeline profitable? | Yes, Japan Lifeline is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Japan Lifeline? | Japan Lifeline's last 12 months EBITDA is $98.9M. |
| What is Japan Lifeline's EBITDA margin? | Japan Lifeline's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Japan Lifeline? | Current EBITDA multiple of Japan Lifeline is 6.6x. |
| What is the current FCF of Japan Lifeline? | Japan Lifeline's last 12 months FCF is $50.8M. |
| What is Japan Lifeline's FCF margin? | Japan Lifeline's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Japan Lifeline? | Current FCF multiple of Japan Lifeline is 12.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
